MedTrace Logo

Dexmedetomidine Versus Ketamine Versus Midazolam in Endoscopic Procedures

NCT04597268 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2023-01-10

No results posted yet for this study

Summary

This study aims to assess the safety and efficacy of dexmedetomidine versus ketamine versus midazolam combined with propofol in cancer patients undergoing gastrointestinal endoscopic procedures.

Conditions

  • Sedation and Analgesia

Interventions

DRUG

Dexmedetomidine

intravenous dexmedetomidine 1 mic/kg

DRUG

Ketamine

ketamine 1mg/kg

DRUG

Midazolam

midazolam 0.05 mg/kg

Sponsors & Collaborators

  • National Cancer Institute, Egypt

    lead OTHER

Principal Investigators

  • Walaa Y Elsabeeny, MD · Lecturer

  • Nahla Y Shehab, MD · Lecturer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-01
Primary Completion
2022-12-15
Completion
2022-12-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04597268 on ClinicalTrials.gov